TIPE1 promotes cervical cancer progression by repression of p53 acetylation and is associated with poor cervical cancer outcome. 2019

Peiqing Zhao, and Xiaoming Pang, and Jie Jiang, and Lianqing Wang, and Xiaolan Zhu, and Yingchun Yin, and Qiaoli Zhai, and Xinxin Xiang, and Fan Feng, and Wenlin Xu
Department of Gynecologic Oncology, The Fourth Affiliated Hospital of Jiangsu University, Zhenjiang, China.

Previous studies have shown that TIPE1 inhibits tumor proliferation and metastasis in certain cancers; however, increased expression of TIPE1 is observed in cervical cancer cell lines and tissues, indicating it might exert a distinctive role in cervical cancer. Cell and xenograft tumorigenicity assays showed that TIPE1 facilitates cervical cancer progression in this study. Further investigation demonstrated that TIPE1 binds to p53 and impairs its activity via inhibition of its acetylation. In addition, TIPE1 promoted cell proliferation and suppressed cisplatin susceptibility in a p53-dependent manner, indicating that TIPE1 facilitates cervical cancer progression primarily through the p53 pathway. TIPE1 expression in clinical samples also demonstrated that its upregulation predicts poor prognosis in patients with cervical cancer. Taken together, the results of this study showed that TIPE1 serves as an oncogene by restricting p53 activity in the development of cervical cancer, suggesting that TIPE1 will provide a new potential target for cervical cancer therapy and can be used as a biomarker to predict patient prognosis.

UI MeSH Term Description Entries
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000107 Acetylation Formation of an acetyl derivative. (Stedman, 25th ed) Acetylations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Peiqing Zhao, and Xiaoming Pang, and Jie Jiang, and Lianqing Wang, and Xiaolan Zhu, and Yingchun Yin, and Qiaoli Zhai, and Xinxin Xiang, and Fan Feng, and Wenlin Xu
January 2019, Frontiers in oncology,
Peiqing Zhao, and Xiaoming Pang, and Jie Jiang, and Lianqing Wang, and Xiaolan Zhu, and Yingchun Yin, and Qiaoli Zhai, and Xinxin Xiang, and Fan Feng, and Wenlin Xu
January 2020, Frontiers in oncology,
Peiqing Zhao, and Xiaoming Pang, and Jie Jiang, and Lianqing Wang, and Xiaolan Zhu, and Yingchun Yin, and Qiaoli Zhai, and Xinxin Xiang, and Fan Feng, and Wenlin Xu
January 2021, Journal of immunology research,
Peiqing Zhao, and Xiaoming Pang, and Jie Jiang, and Lianqing Wang, and Xiaolan Zhu, and Yingchun Yin, and Qiaoli Zhai, and Xinxin Xiang, and Fan Feng, and Wenlin Xu
May 2016, Oncotarget,
Peiqing Zhao, and Xiaoming Pang, and Jie Jiang, and Lianqing Wang, and Xiaolan Zhu, and Yingchun Yin, and Qiaoli Zhai, and Xinxin Xiang, and Fan Feng, and Wenlin Xu
March 2022, Taiwanese journal of obstetrics & gynecology,
Peiqing Zhao, and Xiaoming Pang, and Jie Jiang, and Lianqing Wang, and Xiaolan Zhu, and Yingchun Yin, and Qiaoli Zhai, and Xinxin Xiang, and Fan Feng, and Wenlin Xu
August 2023, Molecular biotechnology,
Peiqing Zhao, and Xiaoming Pang, and Jie Jiang, and Lianqing Wang, and Xiaolan Zhu, and Yingchun Yin, and Qiaoli Zhai, and Xinxin Xiang, and Fan Feng, and Wenlin Xu
June 2023, Cell death discovery,
Peiqing Zhao, and Xiaoming Pang, and Jie Jiang, and Lianqing Wang, and Xiaolan Zhu, and Yingchun Yin, and Qiaoli Zhai, and Xinxin Xiang, and Fan Feng, and Wenlin Xu
May 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Peiqing Zhao, and Xiaoming Pang, and Jie Jiang, and Lianqing Wang, and Xiaolan Zhu, and Yingchun Yin, and Qiaoli Zhai, and Xinxin Xiang, and Fan Feng, and Wenlin Xu
February 2024, Journal of cellular and molecular medicine,
Peiqing Zhao, and Xiaoming Pang, and Jie Jiang, and Lianqing Wang, and Xiaolan Zhu, and Yingchun Yin, and Qiaoli Zhai, and Xinxin Xiang, and Fan Feng, and Wenlin Xu
October 2019, Oncotarget,
Copied contents to your clipboard!